GoodRx Holdings (GDRX) Current Deferred Revenue (2019 - 2023)

GoodRx Holdings has disclosed Current Deferred Revenue across 5 years of filings, most recently posting $10.8 million for Q1 2023.

• Current Deferred Revenue for Q1 2023 came in at $10.8 million, up 4.3% year-over-year; the trailing twelve-month figure through Mar 2023 was $10.8 million (up 4.3% YoY), and the FY2022 annual result was $7.9 million, up 15.01% from the prior year.
• Current Deferred Revenue came in at $10.8 million for Q1 2023 at GoodRx Holdings, up from $7.9 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $11.5 million in Q2 2022 to a low of $3.5 million in Q4 2019.
• The 5-year median for Current Deferred Revenue is $8.5 million (2021), against an average of $8.5 million.
• Across the five-year window, Current Deferred Revenue jumped 98.44% in 2020 and rose 0.25% in 2021, its largest moves.
• GoodRx Holdings' Current Deferred Revenue stood at $3.5 million in 2019, then surged by 98.44% to $6.9 million in 2020, then gained by 0.25% to $6.9 million in 2021, then grew by 15.01% to $7.9 million in 2022, then surged by 36.24% to $10.8 million in 2023.
• The last three Current Deferred Revenue figures came in at $10.8 million (Q1 2023), $7.9 million (Q4 2022), and $11.0 million (Q3 2022), per Business Quant data.